| __timestamp | Catalyst Pharmaceuticals, Inc. | Zoetis Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4473654 | 1643000000 |
| Thursday, January 1, 2015 | 8597010 | 1532000000 |
| Friday, January 1, 2016 | 7910260 | 1364000000 |
| Sunday, January 1, 2017 | 7304399 | 1334000000 |
| Monday, January 1, 2018 | 15875961 | 1484000000 |
| Tuesday, January 1, 2019 | 36881187 | 1638000000 |
| Wednesday, January 1, 2020 | 44233754 | 1726000000 |
| Friday, January 1, 2021 | 49628000 | 2001000000 |
| Saturday, January 1, 2022 | 58183000 | 2009000000 |
| Sunday, January 1, 2023 | 133710000 | 2151000000 |
| Monday, January 1, 2024 | 2318000000 |
Igniting the spark of knowledge
In the dynamic world of pharmaceuticals, understanding the financial strategies of industry players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Zoetis Inc. and Catalyst Pharmaceuticals, Inc. over the past decade.
From 2014 to 2023, Zoetis Inc. consistently outpaced Catalyst Pharmaceuticals in SG&A spending, reflecting its expansive market reach and operational scale. In 2023, Zoetis's SG&A expenses were approximately 16 times higher than those of Catalyst Pharmaceuticals, highlighting its significant investment in administrative and sales functions.
Catalyst Pharmaceuticals showed a remarkable increase in SG&A expenses, growing nearly 30 times from 2014 to 2023. This surge indicates a strategic shift towards aggressive market expansion. Meanwhile, Zoetis maintained a steady growth trajectory, with a 31% increase in SG&A expenses over the same period, underscoring its stable market position.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Zoetis Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Zoetis Inc. and Incyte Corporation
Comparing SG&A Expenses: Zoetis Inc. vs Lantheus Holdings, Inc. Trends and Insights
Selling, General, and Administrative Costs: Zoetis Inc. vs MorphoSys AG
Breaking Down SG&A Expenses: Zoetis Inc. vs Celldex Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Dr. Reddy's Laboratories Limited vs Catalyst Pharmaceuticals, Inc. Trends and Insights
Blueprint Medicines Corporation and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Verona Pharma plc or Catalyst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Vericel Corporation and Catalyst Pharmaceuticals, Inc.